Coronavirus (COVID-19): Important Information From Scripps Learn more

Continuous Glucose Monitoring Study

COVID-19 update:

In response to the COVID pandemic, Scripps Health has temporarily suspended enrollment for all clinical trials. Exceptions will exist for trials with curative intent, life-saving treatment or when no standard of care exists. For questions, please call Scripps Office for the Protection of Research Subjects at 858-678-6402.

Trial ID:
IRB-18-7234
Athena Philis-Tsimikas, M.D.
The MOBILE study looks to see how blood sugar is managed when using a Continuous Glucose Monitor (CGM) compared to fingerstick testing in people with Type 2 Diabetes taking long-acting insulin once or twice a day.

Inclusion Criteria

  • Be 30 years old or older.
  • Have been taking long-acting insulin for the last 6 months.
  • Have stable medications for the last 3 months.
  • Have a smartphone that works with the devices used in the study (smartphone compatibility will be assessed).
  • Have diabetes managed by a primary care physician (PCP), NP, PA, etc.

Exclusion Criteria

  • Have diabetes managed by an endocrinologist.

Additional Info

  • A CGM measures the glucose level in the fluid under the skin. It consists of a sensor which is inserted into the skin, a transmitter attached to the sensor and a display device. Every 5 minutes, the transmitter sends glucose readings to the display device.

Contact Info:

  • Isabel Garcia, RN
  • garcia.maria6@scrippshealth.org
  • 858-309-2602